Goldman Sachs downgraded LivaNova (LIVN) to Neutral from Buy with a price target of $55, down from $56. The firm believes that as the Essenz product cycle passes the halfway point, LivaNova’s decelerating sales growth and slowing rate of margin expansion are likely to limit the potential for multiple expansion. Consensus estimates now more appropriately capture the company’s forward outlook, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIVN:
- LivaNova Appoints Donald Zurbay to Board of Directors
- LivaNova’s Aura6000 Device: A Buy Rating Amidst Promising Market Potential and Competitive Edge
- LivaNova price target raised to $58 from $55 at Barclays
- LivaNova PLC Reports Strong Q2 Earnings and Raised Guidance
- LivaNova PLC Reports Strong Q2 2025 Results